three top democrat republicancontrol hous repres yesterday request gilead scienc ceo john c martin phd give brief price compani new chronic hepat c viru treatment sovaldi sofosbuvir 400 mg tablet complain extraordinari high cost drug
concern treatment cure patient afford three democrat said letter dr martin three henri waxman dca rank member hous committe energi commerc frank pallon jr dnj rank member panel subcommitte health diana degett dco rank member committe subcommitte oversight investig
cite news report gilead plan charg 8400 per 12week treatment sovaldi fda approv decemb six month cost could nearli doubl sovaldi combin drug hous democrat said
cost like high mani patient public insur privat insur rep waxman pallon degett wrote
gilead ha note cost drug lower cost complic associ hepat c treatment liver damag liver failur convers payer price consider efficaci safeti treatment guidelin equal import gilead coo john milligan told bloomberg januari
sovaldi oncedaili oral nucleotid analog polymeras inhibitor design block specif protein need hepat c viru replic sovaldi first drug ha shown safeti efficaci treat certain type hcv infect without need inject interferon time
sovaldi fda prioriti review breakthrough therapi design grant investig medicin deem offer major advanc treatment exist option
hope sovaldi mark begin new era hepat c treatment dr martin declar time statement
